Drug Profile
Research programme: RTK antagonists - Beta Pharma
Latest Information Update: 25 Jul 2023
Price :
$50
*
At a glance
- Originator Beta Pharma
- Class
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal cell carcinoma
Most Recent Events
- 25 Jul 2023 Discontinued - Preclinical for Renal cell carcinoma (Metastatic disease) in USA (unspecified route)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Renal-cell-carcinoma(Metastatic disease) in USA
- 21 Nov 2014 Preclinical trials in Renal cell carcinoma (Metastatic disease) in USA (unspecified route)